Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
AVITA Medical Inc banner

AVITA Medical Inc
NASDAQ:RCEL

Watchlist Manager
AVITA Medical Inc Logo
AVITA Medical Inc
NASDAQ:RCEL
Watchlist
Price: 4.34 USD -3.34% Market Closed
Market Cap: $133.6m
Write Note Create Alert Ask AI

Wall St Price Targets

RCEL Price Targets Summary
AVITA Medical Inc

Wall Street analysts forecast RCEL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RCEL is 4.93 USD with a low forecast of 3.03 USD and a high forecast of 6.3 USD.

RCEL Lowest Forecast
Wall Street Target
$3.03
-30% Downside
RCEL Average Forecast
Wall Street Target
$4.93
14% Upside
RCEL Highest Forecast
Wall Street Target
$6.3
45% Upside
Lowest Forecast
Price Target
3.03 USD
30% Downside
Average Forecast
Price Target
4.93 USD
14% Upside
Highest Forecast
Price Target
6.3 USD
45% Upside
AVITA Medical Inc Competitors:
Price Targets
MRVL
Marvell Technology Group Ltd
29% Upside
TENB
Tenable Holdings Inc
-12% Downside
S
SBC
Sicily By Car SpA
77% Upside
MRVL
Marvell Technology Group Ltd
29% Upside
TENB
Tenable Holdings Inc
-12% Downside
S
SBC
Sicily By Car SpA
77% Upside

Revenue
Forecast

28% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
28% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 3 years, the compound annual growth rate for Revenue has been 28%. The projected CAGR for the next 8 years is 14%.

What are analyst estimates?

Gross Profit
Forecast

28% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
28% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 3 years, the compound annual growth rate for Gross Profit has been 28%. The projected CAGR for the next 8 years is 15%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss

What are analyst estimates?

Continue RCEL Research

Summary
RCEL intrinsic value, competitors valuation, and company profile.
DCF Valuation
RCEL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RCEL stock valuation using valuation multiples.
Wall St Estimates
RCEL price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RCEL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other AVITA Medical Inc listings:
ASX • AUD
AVH
 F • EUR
51KB
 F • EUR
51KA
 OTC • USD
AVHHL
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is RCEL's stock price target?
Price Target
4.93 USD

According to Wall Street analysts, the average 1-year price target for RCEL is 4.93 USD with a low forecast of 3.03 USD and a high forecast of 6.3 USD.

What is the Revenue forecast for AVITA Medical Inc?
Projected CAGR
14%

Over the last 3 years, the compound annual growth rate for Revenue has been 28%. The projected CAGR for the next 8 years is 14%.

What is the Gross Profit forecast for AVITA Medical Inc?
Projected CAGR
15%

Over the last 3 years, the compound annual growth rate for Gross Profit has been 28%. The projected CAGR for the next 8 years is 15%.

Back to Top
ALPHA SPREAD
Follow us
Join 350,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett